ArticleOPEN ACCESS

A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer’s disease

Translational Neurodegeneration
DOI: 10.1186/s40035-023-00387-5
23Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Trial registration : ClinicalTrials.gov Identifier: NCT05821153, Registered April 20 2023, Retrospectively registered, https://classic.clinicaltrials.gov/ct2/show/NCT05821153.

Cite

CITATION STYLE

APA

Faridar, A., Eid, A. M., Thome, A. D., Zhao, W., Beers, D. R., Pascual, M. B., … Appel, S. H. (2023, December 1). A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer’s disease. Translational Neurodegeneration. BioMed Central Ltd. https://doi.org/10.1186/s40035-023-00387-5

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free